// App-Quantinova.ai

POS0022 (2021) : PHARMACOVIGILANCE PREGNANCY DATA IN A LARGE POPULATION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASE EXPOSED TO CERTOLIZUMAB PEGOL: PREGNANCY OUTCOMES AND CONFOUNDERS

Researchers

Presenter

  • M. Clowse

Principal Investigators

  • R. Fischer-Betz

  • C. Nelson-Piercy

  • T. Kumke

  • B. Lauwerys

  • F. Frger

Medical Centers

  • Boston University Medical Center, Division of Rheumatology, Boston, United States of America

  • Heinrich Heine University Düsseldorf, Department for Rheumatology, Düsseldorf, Germany

  • Guy's and St Thomas’ Hospitals NHS Foundation Trust, Department of Women's Health, London, United Kingdom

  • UT Southwestern Medical Center, Department of Pediatrics, Division of Genetics and Metabolism, Dallas, United States of America

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Inselspital, University of Bern, University Clinic for Rheumatology, Immunology and Allergology, Bern, Switzerland

Locations

  • United States

  • Germany

  • United Kingdom

  • Belgium

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved